The Role of Angiotensin Antagonism in Coronary Plaque Regression: Insights from the Glagovian Model
The benefit of antagonizing the effect of the renin angiotensin aldosterone system (RAAS), notably by the use of angiotensin-converting enzyme inhibitor (ACEi) and angiotensin II type 1 receptor blocker (ARB) for coronary artery disease (CAD), has been demonstrated in multiple studies, which may be...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | International Journal of Vascular Medicine |
| Online Access: | http://dx.doi.org/10.1155/2021/8887248 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832558396436381696 |
|---|---|
| author | Abdul H. Alkatiri Doni Firman Amir A. Alkatiri Paskalis I. Suryajaya Albert Sudharsono |
| author_facet | Abdul H. Alkatiri Doni Firman Amir A. Alkatiri Paskalis I. Suryajaya Albert Sudharsono |
| author_sort | Abdul H. Alkatiri |
| collection | DOAJ |
| description | The benefit of antagonizing the effect of the renin angiotensin aldosterone system (RAAS), notably by the use of angiotensin-converting enzyme inhibitor (ACEi) and angiotensin II type 1 receptor blocker (ARB) for coronary artery disease (CAD), has been demonstrated in multiple studies, which may be attributed to their ability to inhibit the deleterious effect of RAAS to the cardiovascular system. It is well known that angiotensin II (Ang II) plays a vital role in atheromatous plaque formation and progression through multiple pathways, including inflammatory and arterial remodeling aspects. Significant coronary atheromatous plaque regression has been previously demonstrated in various studies using statin agents. Similar results have been reported in different studies using angiotensin inhibitor agents, notably ARB agents. Analysis from various trials utilizing ARB showed a significant plaque regression using olmesartan and telmisartan as evaluated by IVUS studies. In contrary, the use of ACEi did not demonstrated significant plaque regression, which may be attributed to the heavy plaque calcification in respective studies. On this review, we aim to present the basic mechanism on the role of RAAS in plaque modulation and its arterial remodeling aspect, which is then integrated with the clinical evidence based on the available intravascular ultrasonography (IVUS) studies on coronary arteries. |
| format | Article |
| id | doaj-art-8875b864abb1434fb3fa33d0309eeec9 |
| institution | Kabale University |
| issn | 2090-2824 2090-2832 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Vascular Medicine |
| spelling | doaj-art-8875b864abb1434fb3fa33d0309eeec92025-02-03T01:32:25ZengWileyInternational Journal of Vascular Medicine2090-28242090-28322021-01-01202110.1155/2021/88872488887248The Role of Angiotensin Antagonism in Coronary Plaque Regression: Insights from the Glagovian ModelAbdul H. Alkatiri0Doni Firman1Amir A. Alkatiri2Paskalis I. Suryajaya3Albert Sudharsono4Department of Cardiology and Vascular Medicine, Hasanuddin University, 90245, IndonesiaDepartment of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, National Cardiovascular Center Harapan Kita, Jakarta 11420, IndonesiaDepartment of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, National Cardiovascular Center Harapan Kita, Jakarta 11420, IndonesiaDepartment of Cardiology and Vascular Medicine, Hasanuddin University, 90245, IndonesiaDepartment of Cardiology and Vascular Medicine, Hasanuddin University, 90245, IndonesiaThe benefit of antagonizing the effect of the renin angiotensin aldosterone system (RAAS), notably by the use of angiotensin-converting enzyme inhibitor (ACEi) and angiotensin II type 1 receptor blocker (ARB) for coronary artery disease (CAD), has been demonstrated in multiple studies, which may be attributed to their ability to inhibit the deleterious effect of RAAS to the cardiovascular system. It is well known that angiotensin II (Ang II) plays a vital role in atheromatous plaque formation and progression through multiple pathways, including inflammatory and arterial remodeling aspects. Significant coronary atheromatous plaque regression has been previously demonstrated in various studies using statin agents. Similar results have been reported in different studies using angiotensin inhibitor agents, notably ARB agents. Analysis from various trials utilizing ARB showed a significant plaque regression using olmesartan and telmisartan as evaluated by IVUS studies. In contrary, the use of ACEi did not demonstrated significant plaque regression, which may be attributed to the heavy plaque calcification in respective studies. On this review, we aim to present the basic mechanism on the role of RAAS in plaque modulation and its arterial remodeling aspect, which is then integrated with the clinical evidence based on the available intravascular ultrasonography (IVUS) studies on coronary arteries.http://dx.doi.org/10.1155/2021/8887248 |
| spellingShingle | Abdul H. Alkatiri Doni Firman Amir A. Alkatiri Paskalis I. Suryajaya Albert Sudharsono The Role of Angiotensin Antagonism in Coronary Plaque Regression: Insights from the Glagovian Model International Journal of Vascular Medicine |
| title | The Role of Angiotensin Antagonism in Coronary Plaque Regression: Insights from the Glagovian Model |
| title_full | The Role of Angiotensin Antagonism in Coronary Plaque Regression: Insights from the Glagovian Model |
| title_fullStr | The Role of Angiotensin Antagonism in Coronary Plaque Regression: Insights from the Glagovian Model |
| title_full_unstemmed | The Role of Angiotensin Antagonism in Coronary Plaque Regression: Insights from the Glagovian Model |
| title_short | The Role of Angiotensin Antagonism in Coronary Plaque Regression: Insights from the Glagovian Model |
| title_sort | role of angiotensin antagonism in coronary plaque regression insights from the glagovian model |
| url | http://dx.doi.org/10.1155/2021/8887248 |
| work_keys_str_mv | AT abdulhalkatiri theroleofangiotensinantagonismincoronaryplaqueregressioninsightsfromtheglagovianmodel AT donifirman theroleofangiotensinantagonismincoronaryplaqueregressioninsightsfromtheglagovianmodel AT amiraalkatiri theroleofangiotensinantagonismincoronaryplaqueregressioninsightsfromtheglagovianmodel AT paskalisisuryajaya theroleofangiotensinantagonismincoronaryplaqueregressioninsightsfromtheglagovianmodel AT albertsudharsono theroleofangiotensinantagonismincoronaryplaqueregressioninsightsfromtheglagovianmodel AT abdulhalkatiri roleofangiotensinantagonismincoronaryplaqueregressioninsightsfromtheglagovianmodel AT donifirman roleofangiotensinantagonismincoronaryplaqueregressioninsightsfromtheglagovianmodel AT amiraalkatiri roleofangiotensinantagonismincoronaryplaqueregressioninsightsfromtheglagovianmodel AT paskalisisuryajaya roleofangiotensinantagonismincoronaryplaqueregressioninsightsfromtheglagovianmodel AT albertsudharsono roleofangiotensinantagonismincoronaryplaqueregressioninsightsfromtheglagovianmodel |